Alex B Blair
Overview
Explore the profile of Alex B Blair including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Blair A, Radomski S, Chou J, Liu M, Howell T, Park W, et al.
Ann Surg Oncol
. 2024 Nov;
32(3):1869-1878.
PMID: 39576455
Background: Pancreatic acinar cell carcinoma (pACC) is a rare neoplasm of the exocrine pancreas. There is a dearth of information about tumor characteristics and patient outcomes. This study describes the...
3.
Blair A, Soares K, Guerrero C, Drebin J, Jarnagin W, He J, et al.
HPB (Oxford)
. 2024 Sep;
26(12):1528-1535.
PMID: 39289133
Background: Adoption of robotic pancreatoduodenectomy (RPD) is growing, although there are challenges for safe introduction of this technique, including limitations in on-site expert proctoring. We developed and implemented a structured...
4.
Li K, Wang J, Zhang R, Zhou J, Espinoza B, Niu N, et al.
J Hematol Oncol
. 2024 Aug;
17(1):62.
PMID: 39113096
Due to the challenge for intratumoral administration, innate agonists have not made it beyond preclinical studies for efficacy testing in most tumor types. Pancreatic ductal adenocarcinoma (PDAC) has a hostile...
5.
Li K, Tandurella J, Gai J, Zhu Q, Lim S, Thomas 2nd D, et al.
Cancer Cell
. 2022 Oct;
40(11):1374-1391.e7.
PMID: 36306792
Successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy necessitates optimization and maintenance of activated effector T cells (Teff). We prospectively collected and applied multi-omic analyses to paired pre- and post-treatment PDAC specimens...
6.
McNeil L, Blair A, Krell R, Zhang C, Ejaz A, Groot V, et al.
Surg Open Sci
. 2022 Sep;
10:97-105.
PMID: 36062077
Background: Recent literature suggests wide variations exist in the international management of locally advanced pancreatic cancer. This study sought to evaluate how geography contributes to variations in management of locally...
7.
Blair A, Wang J, Davelaar J, Baker A, Li K, Niu N, et al.
Gastroenterology
. 2022 Jun;
163(5):1267-1280.e7.
PMID: 35718227
Background & Aims: The stroma in pancreatic ductal adenocarcinoma (PDAC) contributes to its immunosuppressive nature and therapeutic resistance. Herein we sought to modify signaling and enhance immunotherapy efficacy by targeting...
8.
Irfan A, Yang T, Bowring M, Blair A, Duncan M
Am Surg
. 2022 Apr;
89(3):401-406.
PMID: 35448929
Background: Proximal gastrectomy (PG) has been excluded from the arsenal of western surgical oncologists for fear of bile reflux and diet intolerance. However, it is often an appropriate, less morbid...
9.
10.
Blair A, Beckman R, Habib J, Griffin J, Lafaro K, Burkhart R, et al.
HPB (Oxford)
. 2021 Oct;
24(5):645-653.
PMID: 34610896
Background: Main-duct (MD) intraductal papillary mucinous neoplasm (IPMN) is associated with malignancy risk. There is a lack of consensus on treatment (partial or total pancreatectomy) when the MD is diffusely...